ArticleProceedings of the National Academy of Sciences of the United States of America1995
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 252 citations in OpenAlex.
- CHD5 inhibits metastasis of neuroblastoma.Oncogene · 2022Article
- DNA methylation in cord blood in association with prenatal depressive symptoms.Clinical epigenetics · 2021Article
- Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.Cell reports · 2020Article
- Somatic mosaicisms of chromosome 1 at two different stages of ontogenetic development detected by Rh blood group discrepancies.Haematologica · 2019Article
- Article
- Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.Oncotarget · 2016Article
- Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis.Cell death & disease · 2015Review
- The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.The Biochemical journal · 2015Article
- Article
- Article
- Role of CHD5 in human cancers: 10 years later.Cancer research · 2014Review
- Type II diabetes and impaired glucose tolerance due to severe hyperinsulinism in patients with 1p36 deletion syndrome and a Prader-Willi-like phenotype.BMC medical genetics · 2014Article
- Silencing of CHD5 gene by promoter methylation in leukemia.PloS one · 2014Article
- The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.Gene expression patterns : GEP · 2013Article
- High ¹²³I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology.European journal of nuclear medicine and molecular imaging · 2013Article
- Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.PloS one · 2013Article
- Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.PloS one · 2013Article
- Molecular and genetic bases of neuroblastoma.International journal of clinical oncology · 2012Review
- Mechanisms of CHD5 Inactivation in neuroblastomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.PloS one · 2011Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Deletion of the short arm of human chromosome 1 is the most common cytogenetic abnormality observed in neuroblastoma. To characterize the region of consistent deletion, we performed loss of heterozygosity (LOH) studies on 122 neuroblastoma tumor samples with 30 distal chromosome 1p polymorphisms. LOH was detected in 32 of the 122 tumors (26%). A single region of LOH, marked distally by D1Z2 and proximally by D1S228, was detected in all tumors demonstrating loss. Also, cells from a patient with a constitutional deletion of 1p36, and from a neuroblastoma cell line with a small 1p36 deletion, were analyzed by fluorescence in situ hybridization. Cells from both sources had interstitial deletions of 1p36.2-36.3 which overlapped the consensus region of LOH defined by the tumors. Interstitial deletion in the constitutional case was confirmed by allelic loss studies using the panel of polymorphic markers. Four proposed candidate genes--DAN, ID3 (heir-1), CDC2L1 (p58), and TNFR2--were shown to lie outside of the consensus region of allelic loss, as defined by the above deletions. These results more precisely define the location of a neuroblastoma suppressor gene within 1p36.2-36.3, eliminating 33 centimorgans of proximal 1p36 from consideration. Furthermore, a consensus region of loss, which excludes the four leading candidate genes, was found in all tumors with 1p36 LOH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.